ATE463481T1 - Cyclopropylamine als modulatoren des histamin-h3- rezeptors - Google Patents

Cyclopropylamine als modulatoren des histamin-h3- rezeptors

Info

Publication number
ATE463481T1
ATE463481T1 AT06824964T AT06824964T ATE463481T1 AT E463481 T1 ATE463481 T1 AT E463481T1 AT 06824964 T AT06824964 T AT 06824964T AT 06824964 T AT06824964 T AT 06824964T AT E463481 T1 ATE463481 T1 AT E463481T1
Authority
AT
Austria
Prior art keywords
cyclopropylamines
histamine
modulators
receptor
Prior art date
Application number
AT06824964T
Other languages
English (en)
Inventor
Brett Allison
Nicholas I Carruthers
Cheryl A Grice
Michael A Letavic
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE463481T1 publication Critical patent/ATE463481T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
AT06824964T 2005-09-16 2006-09-14 Cyclopropylamine als modulatoren des histamin-h3- rezeptors ATE463481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71765905P 2005-09-16 2005-09-16
PCT/US2006/035877 WO2007035425A2 (en) 2005-09-16 2006-09-14 Cyclopropyl amines as modulators of the histamine h3 receptor

Publications (1)

Publication Number Publication Date
ATE463481T1 true ATE463481T1 (de) 2010-04-15

Family

ID=37889336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824964T ATE463481T1 (de) 2005-09-16 2006-09-14 Cyclopropylamine als modulatoren des histamin-h3- rezeptors

Country Status (33)

Country Link
US (3) US7687499B2 (de)
EP (1) EP1948607B1 (de)
JP (1) JP5185120B2 (de)
KR (1) KR101336106B1 (de)
CN (1) CN101321730B (de)
AR (1) AR058670A1 (de)
AT (1) ATE463481T1 (de)
AU (1) AU2006292598B2 (de)
BR (1) BRPI0622428A2 (de)
CA (1) CA2622760C (de)
CR (1) CR9891A (de)
CY (1) CY1110167T1 (de)
DE (1) DE602006013501D1 (de)
DK (1) DK1948607T3 (de)
EA (1) EA014370B1 (de)
EC (1) ECSP088279A (de)
ES (1) ES2342323T3 (de)
HK (1) HK1123291A1 (de)
HR (1) HRP20100263T1 (de)
IL (1) IL190110A (de)
ME (1) ME01181B (de)
MX (1) MX2008003691A (de)
MY (1) MY145305A (de)
NO (1) NO340949B1 (de)
NZ (1) NZ566533A (de)
PL (1) PL1948607T3 (de)
PT (1) PT1948607E (de)
RS (1) RS51311B (de)
SI (1) SI1948607T1 (de)
TW (1) TWI418552B (de)
UA (1) UA96424C2 (de)
WO (1) WO2007035425A2 (de)
ZA (1) ZA200803337B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423147B2 (en) * 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
EP1948607B1 (de) 2005-09-16 2010-04-07 Janssen Pharmaceutica, N.V. Cyclopropylamine als modulatoren des histamin-h3-rezeptors
US7795426B2 (en) * 2005-10-31 2010-09-14 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
EA201001872A1 (ru) * 2005-10-31 2011-04-29 Янссен Фармацевтика Н.В. Новые способы получения производных циклопропиламида
EA015555B1 (ru) * 2006-05-30 2011-08-30 Янссен Фармацевтика Н.В. Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
WO2007150010A2 (en) * 2006-06-23 2007-12-27 Abbott Laboratories Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2007265238A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine H3 receptor
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
PT2121636T (pt) * 2006-12-14 2017-04-26 Janssen Pharmaceutica Nv Processo para a preparação de derivados de piperazinil e diazepanil benzamida
WO2009024823A2 (en) 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP2222664B1 (de) 2007-11-20 2014-10-29 Janssen Pharmaceutica, N.V. Cycloalkyloxy- und heterocycloalkyloxypyridinverbindungen als modulatoren des histamin-h3-rezeptors
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
EP2536702A4 (de) * 2010-02-18 2013-07-10 Astrazeneca Ab Neue kristalline form eines cyclopropylbenzamidderivats
JP5746718B2 (ja) * 2010-02-18 2015-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ シクロプロピルアミド誘導体からなる固体形態
JP6166177B2 (ja) 2010-05-14 2017-07-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US20130339859A1 (en) 2012-06-15 2013-12-19 Muzik LLC Interactive networked headphones
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10088921B2 (en) 2014-10-10 2018-10-02 Muzik Inc. Devices for sharing user interactions
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
US3886160A (en) 1972-09-28 1975-05-27 Searle & Co 2-(2-Methyl-5-nitro-1-imidazolyl) ethyl-2-thiopseudoureas
FR2543139B1 (fr) * 1983-03-22 1985-08-16 Cerm Cent Europ Rech Mauvernay Derives de (1-alcoxy 2-amino) ethyl pyridine ou pyrazine, leur preparation et leur application en therapeutique
JPH0641455B2 (ja) 1984-12-10 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JP2813747B2 (ja) 1989-05-22 1998-10-22 富士写真フイルム株式会社 画像形成法
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO1996019221A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1059954A (ja) 1996-08-14 1998-03-03 Takeda Chem Ind Ltd 環状アミン誘導体およびそれを含んでなる医薬
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
RU2216549C2 (ru) 1997-11-07 2003-11-20 Дайити Фармасьютикал Ко., Лтд. Пиперазин-циклодекстриновый комплекс и лекарственное средство, содержащее указанный комплекс
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0978512A1 (de) 1998-07-29 2000-02-09 Societe Civile Bioprojet Aryloxy- (oder Arylthio)alkylamine ohne Imidazolring als Histamin-H3-Antagonisten und deren therapeutische Anwendung
WO2002012214A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines as h3 receptor ligands
WO2002012190A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
EP1351946A2 (de) 2000-09-01 2003-10-15 Icos Corporation Materialien und methoden für krebs-therapie
CA2423284A1 (en) 2000-09-22 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2003000314A2 (en) 2001-06-20 2003-01-03 The Regents Of The University Of California Hemodialysis system and method
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
DE60234616D1 (de) 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
EP1430027B1 (de) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
EP1444219A1 (de) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituierte piperidine und deren verwendung zur behandlung von krankheiten, die mit dem histamin-h3-rezeptor in zusammenhang stehen
KR20040068202A (ko) 2001-12-10 2004-07-30 오르토-맥네일 파마슈티칼, 인코퍼레이티드 페닐알킨
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CN1625554A (zh) 2002-02-01 2005-06-08 诺沃挪第克公司 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
BR0307429A (pt) * 2002-02-05 2004-12-28 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
AU2003301552B2 (en) 2002-10-23 2010-04-22 Janssen Pharmaceutica, N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
AU2005317928B2 (en) 2004-12-24 2010-06-10 Astrazeneca Ab Heterocyclic compounds as CCR2b antagonists
EP1948607B1 (de) 2005-09-16 2010-04-07 Janssen Pharmaceutica, N.V. Cyclopropylamine als modulatoren des histamin-h3-rezeptors
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
EA014370B1 (ru) 2010-10-29
NO20081788L (no) 2008-05-29
US20110136797A1 (en) 2011-06-09
NO340949B1 (no) 2017-07-24
TWI418552B (zh) 2013-12-11
AR058670A1 (es) 2008-02-20
PT1948607E (pt) 2010-06-02
US20070066821A1 (en) 2007-03-22
ME01181B (me) 2013-03-20
IL190110A (en) 2014-01-30
DE602006013501D1 (de) 2010-05-20
PL1948607T3 (pl) 2010-09-30
CA2622760A1 (en) 2007-03-29
EP1948607A2 (de) 2008-07-30
KR101336106B1 (ko) 2013-12-05
US7910582B2 (en) 2011-03-22
CY1110167T1 (el) 2015-01-14
CN101321730B (zh) 2012-11-14
US8026242B2 (en) 2011-09-27
NZ566533A (en) 2010-11-26
ECSP088279A (es) 2008-04-28
HK1123291A1 (en) 2009-06-12
CR9891A (es) 2009-01-16
AU2006292598B2 (en) 2012-06-21
WO2007035425A3 (en) 2008-07-24
JP2009508864A (ja) 2009-03-05
US20100130485A1 (en) 2010-05-27
DK1948607T3 (da) 2010-07-26
US7687499B2 (en) 2010-03-30
AU2006292598A1 (en) 2007-03-29
BRPI0622428A2 (pt) 2021-05-11
MY145305A (en) 2012-01-13
ZA200803337B (en) 2009-10-28
EA200800835A1 (ru) 2008-12-30
CA2622760C (en) 2012-12-04
ES2342323T3 (es) 2010-07-05
EP1948607B1 (de) 2010-04-07
UA96424C2 (ru) 2011-11-10
HRP20100263T1 (hr) 2010-06-30
SI1948607T1 (sl) 2010-07-30
CN101321730A (zh) 2008-12-10
MX2008003691A (es) 2009-02-27
KR20080056198A (ko) 2008-06-20
IL190110A0 (en) 2008-12-29
WO2007035425A2 (en) 2007-03-29
TW200804337A (en) 2008-01-16
RS51311B (sr) 2010-12-31
JP5185120B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
ATE463481T1 (de) Cyclopropylamine als modulatoren des histamin-h3- rezeptors
CY2017008I1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
IL195514A0 (en) Substituted pyridiyl amide compounds as modulators of the histamine h3 receptor
BRPI0919172A2 (pt) compostos os quais modulam seletivamente o receptor de cb2
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
DE602007008222D1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
BRPI0821258A2 (pt) Derivados de ciclopropilamina
ATE492543T1 (de) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren
HK1147994A1 (en) Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor h3
DE112005002826A5 (de) Ausgleichseinheit
ATE512137T1 (de) Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors
FI7025U1 (fi) Laite sinilevän torjumiseksi tai rajoittamiseksi
ATE553108T1 (de) Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors
DE602006018334D1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
FR2891181B1 (fr) Dispositf pour la fente de buches
DE602006020489D1 (de) Cb1-rezeptormodulatoren
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
ITMI20052367A1 (it) Cristallizzatore
DE602006005006D1 (de) Als modulatoren des glucocorticoidrezeptors geeignete nichtsteroidale verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1948607

Country of ref document: EP